Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Atadja

Showing results (61-70 of 102) with videos related to

Pageof 11
Sort By:
Neoplasia (New York, N.Y.)|April 9, 2008
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenograftsYuen-Li Chung, Helen Troy, Rebecca Kristeleit, et al.
Journal of Medicinal Chemistry|February 8, 2002
Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamatesStacy W Remiszewski, Lidia C Sambucetti, Peter Atadja, et al.
Blood|April 23, 2009
The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacyLeigh Ellis, Michael Bots, Ralph K Lindemann, et al.
Free Radical Biology & Medicine|November 17, 2010
Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cellsPiergiorgio Pettazzoni, Stefania Pizzimenti, Cristina Toaldo, et al.
Cancer Biology & Therapy|March 13, 2009
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cellsWarren Fiskus, Kate Buckley, Rekha Rao, et al.
Blood|July 29, 2008
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cellsWarren Fiskus, Rekha Rao, Pravina Fernandez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2012
The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllinMiguel Lemaire, Charlotte Fristedt, Prasoon Agarwal, et al.
Genome Research|July 11, 2015
SETDB1 modulates PRC2 activity at developmental genes independently of H3K9 trimethylation in mouse ES cellsQi Fei, Xiaoqin Yang, Hua Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survivalElke De Bruyne, Tomas Jan Bos, Kewal Asosingh, et al.
Blood|September 3, 2010
Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonistsAditya Mandawat, Warren Fiskus, Kathleen M Buckley, et al.
Pageof 11

Showing results (61-70 of 102) with videos related to

Sort By:
Pageof 11
Neoplasia (New York, N.Y.)|April 9, 2008
Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenograftsYuen-Li Chung, Helen Troy, Rebecca Kristeleit, et al.
Journal of Medicinal Chemistry|February 8, 2002
Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamatesStacy W Remiszewski, Lidia C Sambucetti, Peter Atadja, et al.
Blood|April 23, 2009
The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacyLeigh Ellis, Michael Bots, Ralph K Lindemann, et al.
Free Radical Biology & Medicine|November 17, 2010
Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cellsPiergiorgio Pettazzoni, Stefania Pizzimenti, Cristina Toaldo, et al.
Cancer Biology & Therapy|March 13, 2009
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cellsWarren Fiskus, Kate Buckley, Rekha Rao, et al.
Blood|July 29, 2008
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cellsWarren Fiskus, Rekha Rao, Pravina Fernandez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2012
The HDAC inhibitor LBH589 enhances the antimyeloma effects of the IGF-1RTK inhibitor picropodophyllinMiguel Lemaire, Charlotte Fristedt, Prasoon Agarwal, et al.
Genome Research|July 11, 2015
SETDB1 modulates PRC2 activity at developmental genes independently of H3K9 trimethylation in mouse ES cellsQi Fei, Xiaoqin Yang, Hua Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2008
Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survivalElke De Bruyne, Tomas Jan Bos, Kewal Asosingh, et al.
Blood|September 3, 2010
Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonistsAditya Mandawat, Warren Fiskus, Kathleen M Buckley, et al.
Pageof 11